Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932477 · ClinicalTrials.gov registry record · NA
Safety and Tolerability of Artificial Tears in Dry Eye Subjects
A NA study, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT00932477: Completed NA study, sponsored by Allergan.
NCT00932477 is a NA study that has completed, run by Allergan. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00932477, a NA study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The safety and tolerability of two new artificial tears will be compared to a currently-available artificial tear in subjects with dry eye. Each subject will receive all three products in a randomly assigned order. The subject will use one product at a time for a duration of one week before switching to the next assigned product.
Primary Outcome
Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst.
Interventions
- DRUG Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
- DRUG Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
- DRUG Glycerin and Polysorbate 80 based artificial tear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-08 |
| Est. Completion | 2009-09 |
| Phase | NA |
What the finished NCT00932477 record still lists
NCT00932477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear is the first listed.
NCT00932477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00932477 about?
NCT00932477 is a clinical study titled "Safety and Tolerability of Artificial Tears in Dry Eye Subjects". The safety and tolerability of two new artificial tears will be compared to a currently-available artificial tear in subjects with dry eye. Each subject will receive all three products in a randomly assigned order. The subject will use one product at a time for a duration of one week before switchin...
What is the current status of trial NCT00932477?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2009-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00932477?
The interventions under investigation include: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear (DRUG), Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear (DRUG), Glycerin and Polysorbate 80 based artificial tear (DRUG).
Who is sponsoring clinical trial NCT00932477?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00932477's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia